Atlanta, GA, April 26, 2023 – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing vaccines and immunotherapies against cancers and infectious diseases, today announced its participation in and sponsor support of the 4th Symposium on Infectious Diseases in the Immunocompromised Host, being held April 30 to May 2, 2023, in Seattle, Washington and hosted by the Fred Hutchinson Cancer Center. Medical leadership representation from GeoVax will attend the event and will meet and interact with the symposium speakers and attendees.

The 4th Symposium on Infectious Diseases in the Immunocompromised Host brings together leaders and trainees in research and clinical care of infectious diseases in the immunocompromised host. The program features outstanding, internationally recognized experts in the field, representing more than 20 institutions, who will speak on topics including infections in solid organ transplant, hematopoietic cell transplant, and oncology. The symposium will address COVID-19, fungal disease, respiratory viruses, CMV, HHV-6, immunotherapy, the microbiome, and antimicrobial stewardship.

David Dodd, GeoVax’s Chairman and CEO, commented, “We are proud to participate in this important symposium which highlights the critical need for innovative approaches to preventing and treating infections in vulnerable populations. At GeoVax, we remain committed to advancing novel vaccine technologies such as CM04S1, our next-generation COVID-19 vaccine being studied in two Phase 2 trials, that can potentially help protect and improve the lives of immunocompromised individuals, representing those who are most susceptible to infectious diseases.”

About GeoVax

GeoVax Labs, Inc. is a clinical-stage biotechnology company developing novel therapies and vaccines for cancers and many of the world’s most threatening infectious diseases. The company’s lead program in oncology is a novel oncolytic solid tumor gene-directed therapy, Gedeptin^®, presently in a multicenter Phase 1/2 clinical trial for advanced head and neck cancers. GeoVax’s lead infectious disease candidate is GEO-CM04S1, a next-generation COVID-19 vaccine targeting high-risk immunocompromised patient populations. Currently in two Phase 2 clinical trials, GEO-CM04S1 is being evaluated as a COVID-19 vaccine for immunocompromised patients such as those suffering from hematologic cancers and other patient populations for whom the current authorized COVID-19 vaccines are insufficient. In addition, GEO-CM04S1 is in a Phase 2 clinical trial evaluating the vaccine as a more robust, durable COVID-19 booster among healthy patients who previously received the mRNA vaccines. GeoVax has a leadership team who have driven significant value creation across multiple life science companies over the past several decades.

For additional information about GeoVax, visit our website: www.geovax.com.

Investor Relations Contact:

Rich Cockrell

CG Capital

404-736-3838

This email address is being protected from spambots. You need JavaScript enabled to view it.